GlaxoSmithKline | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.52B 1.73B 2024-12
Alcon AG USD 1.83B 112M 2024-12
Almirall EUR 329.41M 15.11M 2024-06
Amgen USD 11.97B 2.96B 2024-12
AstraZeneca USD 5.49B 691M 2024-12
Bayer EUR 6.19B 1.57B 2024-12
Biogen USD 2.38B 675.8M 2024-12
Bristol-Myers Squibb USD 10.35B 2.46B 2024-12
Eli Lilly USD 3.27B 100.6M 2024-12
Fresenius EUR 2.28B 788M 2024-12
Fresenius Medical Care EUR 1.18B 191M 2024-12
Galapagos EUR 64.24M 8.72M 2024-12
Genmab DKK 9.86B 3.52B 2024-12
Gilead Sciences USD 9.99B 4.95B 2024-12
GlaxoSmithKline GBP 3.87B 678M 2024-12
Glaxosmithkline GBP 3.87B 678M 2024-12
GRIFOLS EUR 979.78M 334.84M 2024-12
Hikma Pharmaceutical USD 0 1000K 2024-06
Lonza CHF 1.11B 286M 2024-12
Merck EUR 3.16B 476M 2024-09
Merck USD 13.24B 1.35B 2024-12
Novartis USD 8.87B 4.74B 2024-12
Orion EUR 205.6M 15.5M 2024-12
Pfizer USD 1.04B 49M 2024-12
Philips EUR 2.4B 594M 2024-12
Recordati EUR 235.02M 34.44M 2024-09
Regeneron Pharmaceuticals USD 17.91B 15.9B 2024-12
Roche Holding CHF 6.98B 2.15B 2024-12
Sanofi 6.8B 1.92B 2024-06
Smith & Nephew 568M 266M 2024-06
UCB EUR 1.57B 1.14B 2024-12



GlaxoSmithKline Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Mar 2025.